Keytrida plus Lenvima improved survival and duration of response in patients with advanced hepatocellular carcinoma. Adding Keytruda (pembrolizumab) to Lenvima (lenvatinib) led to better duration of ...
Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
Among the 27 responding patients, 81% had a duration of response (DOR) of six months or longer, and 37% had a DOR of 12 months or longer. In June 2020, KEYTRUDA was granted its first indication in ...
The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...
BioNTech has added evidence that PD-(L)1xVEGF-A bispecifics can unseat Keytruda. The German biotech reported an 18-month overall survival rate of 69.7% in a phase 1b/2 breast cancer trial, handily ...
After AstraZeneca’s Imfinzi last year claimed new territory in the biliary tract cancer space, Merck’s Keytruda has hit the scene with an FDA nod to match its rival. The approval in locally advanced ...
How Does Keytruda Work for RCC? Some cancer cells have what are called checkpoint proteins known as PD-L1 on their cell surface. Some immune cells in our bodies called T cells have proteins on their ...
Merck & Co.’s Keytruda has added a third bladder cancer use to its label. With an FDA nod Wednesday, Keytruda has become the first PD-1/L1 inhibitor approved to treat patients with superficial but ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results